, Volume 190, Issue 4, pp 451–458 | Cite as

Idiopathic Pulmonary Fibrosis is Associated with Circulating Antiepithelial Antibodies

  • Ahmed Fahim
  • Mei C. Chong
  • Michael G. Crooks
  • Simon P. Hart



Idiopathic pulmonary fibrosis (IPF) is a restrictive fibrotic lung disease of uncertain etiology. Alveolar epithelial injury may be one of the inciting triggers in the pathogenesis of this disorder. We hypothesized that circulating antibodies to alveolar epithelial and endothelial cells may be involved in the pathogenesis of IPF.


Antibodies to alveolar epithelial and endothelial cells were analyzed by indirect immunofluorescence using alveolar epithelial cells (A549) and human umbilical vein endothelial cells respectively. IgG and IgM antibodies in patients’ serum were evaluated. Patterns of immunofluorescence, including membranous, cytoplasmic, and nuclear staining, were analyzed by fluorescence microscopy. The severity of immunofluorescence was divided into mild, moderate, and severe categories. Fifty-six patients (IPF = 28, non-IPF ILD = 9, non-ILD control = 19) were evaluated for antiepithelial antibodies, and 28 patients (IPF = 12, non-IPF ILD = 3, non-ILD control = 13) were studied for antiendothelial antibodies.


Compared with control subjects, serum from IPF patients displayed significantly higher IgG binding to alveolar epithelial cells (P = 0.041) with a membranous pattern of immunofluorescence. However, there was no significant difference in immunofluorescence with IgG on endothelial cells (P = 0.165). In terms of IgM antibodies, there was no differential fluorescence observed for either epithelial or endothelial cells.


There is evidence of increased IgG antibodies directed against alveolar epithelium in IPF. These antibodies may play a significant role in the pathogenesis of this fibrotic disorder. The findings of this study suggest further evaluation of the role of immune mediated alveolar epithelial injury in IPF.


Antiendothelial antibodies Antiepithelial antibodies Idiopathic pulmonary fibrosis Interstitial lung disease Immunofluorescence 


  1. 1.
    Lynch JP III, Wurfel M, Flaherty K, White E, Martinez F, Travis W, Raghu G (2001) Usual interstitial pneumonia. Semin Respir Crit Care Med 22(4):357–386PubMedCrossRefGoogle Scholar
  2. 2.
    King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA (2005) Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 127(1):171–177PubMedCrossRefGoogle Scholar
  3. 3.
    King TE Jr, Behr J, Brown KK, Du Bois RM, Lancaster L, de Andrade JA, Stahler G, Leconte I, Roux S, Raghu G (2008) BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177(1):75–81PubMedCrossRefGoogle Scholar
  4. 4.
    Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr (2004) A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350(2):125–133PubMedCrossRefGoogle Scholar
  5. 5.
    Raghu G, Brown KK, Costabel U, Cottin V, Du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, Fatenejad S (2008) Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 178(9):948–955PubMedCrossRefGoogle Scholar
  6. 6.
    Carrington CB, Gaensler EA, Coutu RE, FitzGerald MX, Gupta RG (1978) Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 298(15):801–809PubMedCrossRefGoogle Scholar
  7. 7.
    Katzenstein AA, Askin FB (1982) Surgical pathology of non-neoplastic lung disease. Major Probl Pathol 13:1–430PubMedGoogle Scholar
  8. 8.
    Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski JM, Gadgil A, George MP, Gibson KF, Choi AM, Kaminski N, Zhang Y, Duncan SR (2007) Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol 179(4):2592–2599PubMedGoogle Scholar
  9. 9.
    Fujita J, Dobashi N, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Tokuda M, Hojo S, Okada H, Takahara J (1999) Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders. Lung 177(5):311–319PubMedCrossRefGoogle Scholar
  10. 10.
    Fujita J, Takeuchi T, Dobashi N, Ohtsuki Y, Tokuda M, Takahara J (1999) Detection of anti-ADAM 10 antibody in serum of a patient with pulmonary fibrosis associated with dermatomyositis. Ann Rheum Dis 58(12):770–772PubMedCrossRefGoogle Scholar
  11. 11.
    Erlinger R, Rauh G, Behr J, Schumacher U, Welsch U, Zollner N (1991) Similar frequency of autoantibodies against pneumocytes type II and Clara cells in patients with interstitial lung diseases and healthy persons. Klin Wochenschr 69(7):297–302PubMedCrossRefGoogle Scholar
  12. 12.
    Meliconi R, Bestagno M, Sturani C, Negri C, Galavotti V, Sala C, Facchini A, Ciarrocchi G, Gasbarrini G, Astaldi Ricotti GC (1989) Autoantibodies to DNA topoisomerase II in cryptogenic fibrosing alveolitis and connective tissue disease. Clin Exp Immunol 76(2):184–189PubMedGoogle Scholar
  13. 13.
    Meliconi R, Negri C, Borzi RM, Facchini A, Sturani C, Fasano L, Fabbri M, Astaldi Ricotti GC (1993) Antibodies to topoisomerase II in idiopathic pulmonary fibrosis. Clin Rheumatol 12(3):311–315PubMedCrossRefGoogle Scholar
  14. 14.
    Wallace WA, Roberts SN, Caldwell H, Thornton E, Greening AP, Lamb D, Howie SE (1994) Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis. Thorax 49(3):218–224PubMedCrossRefGoogle Scholar
  15. 15.
    Taille C, Grootenboer-Mignot S, Boursier C, Michel L, Debray MP, Fagart J, Barrientos L, Mailleux A, Cigna N, Tubach F, Marchal-Somme J, Soler P, Chollet-Martin S, Crestani B (2011) Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183(6):759–766PubMedCrossRefGoogle Scholar
  16. 16.
    American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS) [Review] [234 refs]. Am J Respir Crit Care Med 161(2 Pt 1):646–664Google Scholar
  17. 17.
    Kim JH, Jang YS, Eom KS, Hwang YI, Kang HR, Jang SH, Kim CH, Park YB, Lee MG, Hyun IG, Jung KS, Kim DG (2007) Transforming growth factor beta1 induces epithelial-to-mesenchymal transition of A549 cells. J Korean Med Sci 22(5):898–904PubMedCrossRefGoogle Scholar
  18. 18.
    Strieter RM (2005) Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest 128(5 Suppl 1):526S–532SPubMedCrossRefGoogle Scholar
  19. 19.
    Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Tokuda M, Hojo S, Bandou S, Ueda Y, Takahara J (2000) Circulating cytokeratin 8: anti-cytokeratin 8 antibody immune complexes in sera of patients with pulmonary fibrosis. Respiration 67(4):397–401PubMedCrossRefGoogle Scholar
  20. 20.
    Dobashi N, Fujita J, Murota M, Ohtsuki Y, Yamadori I, Yoshinouchi T, Ueda R, Bandoh S, Kamei T, Nishioka M, Ishida T, Takahara J (2000) Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 178(3):171–179PubMedCrossRefGoogle Scholar
  21. 21.
    Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Takahara J (1999) Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia. Eur Respir J 14(3):574–578PubMedCrossRefGoogle Scholar
  22. 22.
    Fujita J, Bandoh S, Ohtsuki Y, Dobashi N, Hiroi M, Takeuchi T, Fukunaga Y, Miyaue H, Onishi S, Ishida T, Takahara J (2000) The role of anti-epithelial cell antibodies in the pathogenesis of bilateral radiation pneumonitis caused by unilateral thoracic irradiation. Respir Med 94(9):875–880PubMedCrossRefGoogle Scholar
  23. 23.
    Fujita J, Ohtsuki Y, Bandoh S, Takashima H, Ueda Y, Wu F, Tojo Y, Kubo A, Ishida T (2004) Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis: possible marker of epithelial cell damage. Respir Med 98(4):294–300PubMedCrossRefGoogle Scholar
  24. 24.
    Ward PA (1979) Immune complex injury of the lung. Am J Pathol 97(1):85–92PubMedGoogle Scholar
  25. 25.
    Magro CM, Ross P, Marsh CB, Allen JN, Liff D, Knight DA, Waldman WJ, Cowden DJ (2007) The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease. Am J Clin Pathol 127(2):237–247PubMedCrossRefGoogle Scholar
  26. 26.
    Magro CM, Waldman WJ, Knight DA, Allen JN, Nadasdy T, Frambach GE, Ross P, Marsh CB (2006) Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Hum Immunol 67(4–5):284–297PubMedCrossRefGoogle Scholar
  27. 27.
    Magro CM, Allen J, Pope-Harman A, Waldman WJ, Moh P, Rothrauff S, Ross P Jr (2003) The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am J Clin Pathol 119(4):556–567PubMedCrossRefGoogle Scholar
  28. 28.
    Bellon B, Bernaudin JF, Mandet C, Chamak B, Kuhn J, Druet P (1982) Immune complex-mediated lung injury produced by horseradish peroxidase (HRP) and anti-HRP antibodies in rats. Am J Pathol 107(1):16–24PubMedGoogle Scholar
  29. 29.
    Dall’Aglio PP, Pesci A, Bertorelli G, Brianti E, Scarpa S (1988) Study of immune complexes in bronchoalveolar lavage fluids. Respiration 54(Suppl 1):36–41PubMedCrossRefGoogle Scholar
  30. 30.
    Dreisin RB, Schwarz MI, Theofilopoulos AN, Stanford RE (1978) Circulating immune complexes in the idiopathic interstitial pneumonias. N Engl J Med 298(7):353–357PubMedCrossRefGoogle Scholar
  31. 31.
    Haslam PL, Thompson B, Mohammed I, Townsend PJ, Hodson ME, Holborow EJ, Turner-Warwick M (1979) Circulating immune complexes in patients with cryptogenic fibrosing alveolitis. Clin Exp Immunol 37(3):381–390PubMedGoogle Scholar
  32. 32.
    Bournazos S, Bournazou I, Murchison JT, Wallace WA, McFarlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP (2010) Fcgamma receptor IIIb (CD16b) polymorphisms are associated with susceptibility to idiopathic pulmonary fibrosis. Lung 188(6):475–481PubMedCrossRefGoogle Scholar
  33. 33.
    Bournazos S, Grinfeld J, Alexander KM, Murchison JT, Wallace WA, McFarlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP (2010) Association of FcgammaR IIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression. BMC Pulm Med 10:51PubMedCrossRefGoogle Scholar
  34. 34.
    Wallace WA, Schofield JA, Lamb D, Howie SE (1994) Localisation of a pulmonary autoantigen in cryptogenic fibrosing alveolitis. Thorax 49(11):1139–1145PubMedCrossRefGoogle Scholar
  35. 35.
    Marrack P, Kappler J, Kotzin BL (2001) Autoimmune disease: why and where it occurs. Nat Med 7(8):899–905PubMedCrossRefGoogle Scholar
  36. 36.
    Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, Hansell DM, Du Bois RM, Wells AU (2010) Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 35(4):830–836PubMedCrossRefGoogle Scholar
  37. 37.
    Takabatake N, Arao T, Sata M, Abe S, Inoue S, Shibata Y, Takeishi Y, Kubota I (2005) Involvement of pulmonary endothelial cell injury in the pathogenesis of pulmonary fibrosis: clinical assessment by 123I-MIBG lung scintigraphy. Eur J Nucl Med Mol Imaging 32(2):221–228PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Ahmed Fahim
    • 1
  • Mei C. Chong
    • 2
  • Michael G. Crooks
    • 1
  • Simon P. Hart
    • 3
  1. 1.Division of Cardiovascular and Respiratory StudiesCastle Hill HospitalCottinghamUK
  2. 2.Hull York Medical SchoolCottinghamUK
  3. 3.Division of Cardiovascular and Respiratory Studies, Centre for Cardiovascular and Metabolic ResearchHull York Medical School, Castle Hill HospitalCottinghamUK

Personalised recommendations